<DOC>
	<DOCNO>NCT00638898</DOCNO>
	<brief_summary>RATIONALE : Giving high-dose chemotherapy autologous stem cell transplant stop growth tumor cell stop divide kill . Giving colony-stimulating factor , G-CSF , help stem cell move bone marrow blood collect store . Chemotherapy give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy . PURPOSE : This clinical trial study well give busulfan , melphalan , topotecan hydrochloride together stem cell transplant work treat patient newly diagnose relapse solid tumor .</brief_summary>
	<brief_title>Busulfan , Melphalan , Topotecan Hydrochloride , Stem Cell Transplant Treating Patients With Newly Diagnosed Relapsed Solid Tumor</brief_title>
	<detailed_description>OBJECTIVES : I . To assess feasibility novel combination condition therapy busulfan/melphalan topotecan follow autologous hematopoietic stem cell transplantation ( HSCT ) patient relapse , refractory and/or poor risk pediatric solid tumor . II . To determine within confines pilot study , myeloid platelet engraftment , overall survival disease-free survival patient relapse , refractory pediatric solid tumor patient solid tumor poor risk factor time diagnosis . III . To determine pharmacokinetics topotecan . OUTLINE : AUTOLOGOUS HEMATOPOIETIC STEM CELL OR AUTOLOGOUS BONE MARROW COLLECTION : Patients undergo stem cell mobilization per institutional guideline G-CSF IV subcutaneously , continue completion leukapheresis . Patients undergo apheresis mobilization continue minimum 2.0 x 10^6 CD34 cells/kg collect . Cells process cryopreserved following institutional guideline . Patients collect &gt; 2.0 x 10^6 CD34+ cells/kg may proceed high-dose chemotherapy . HIGH-DOSE CHEMOTHERAPY : Patients receive topotecan hydrochloride IV continuously 24 hour day -8 -4 , busulfan IV every 6 hour day -8 -4 , melphalan IV 30 minute day -3 -2 . AUTOLOGOUS HEMATOPOIETIC STEM CELL OR AUTOLOGOUS BONE MARROW REINFUSION : Patients undergo autologous hematopoietic stem cell transplantation autologous bone marrow transplantation day 0 . Patients also receive G-CSF IV daily begin day +5 continue blood count recover . After completion study treatment , patient follow every 3 month 1 year annually thereafter .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Germinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Rhabdomyosarcoma , Embryonal</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive , Peripheral</mesh_term>
	<mesh_term>Optic Nerve Glioma</mesh_term>
	<mesh_term>Pinealoma</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Inclusion Patients relapse neuroblastoma , rhabdomyosarcoma , Ewing 's sarcoma , PNET , brain tumor , soft tissue sarcoma , Wilm 's tumor , germ cell tumor solid tumor achieve least partial response ( PR ) chemotherapy , surgery , radiotherapy Newly diagnose patient poorrisk pediatric solid tumor : metastatic Ewing 's , metastatic PNET , rhabdomyosarcoma , soft tissue sarcoma , octeomesenchymoma , others high risk relapse achieve least partial response ( PR ) chemotherapy , surgery , radiotherapy For category , attempt achieve complete response ( CR ) PR make ; pretransplant modality may include surgery , chemotherapy , radiation therapy ; radiation must include lung field ; patient CR PR primary site eligible HIGHDOSE CHEMOTHERAPY : Histologically confirm diagnosis Anatomic Pathology Department ; recurrent metastatic disease , histologic confirmation obtain , exception brain stem tumor ; neuroblastoma , demonstration marrow metastasis elevate urinary catecholamine adequate diagnosis HIGHDOSE CHEMOTHERAPY : No contraindication stem cell collection apheresis bone marrow harvest HIGHDOSE CHEMOTHERAPY : All patient , legal guardian must sign voluntary informed consent accordance institutional federal guideline HIGHDOSE CHEMOTHERAPY : Adequate renal function demonstrate creatinine clearance ( 12 24 hour urine collection ) glomerular filtration rate ( GFR ) &gt; 60 ml/min/1.73m^2 HIGHDOSE CHEMOTHERAPY : Adequate cardiac function demonstrate ejection fraction &gt; 55 % echocardiogram MUGA HIGHDOSE CHEMOTHERAPY : Adequate hepatic function demonstrate bilirubin &lt; 2 mg/dL , SGOT SGPT &lt; 5 x upper limit normal HIGHDOSE CHEMOTHERAPY : Adequate bone marrow function evidence platelet count &gt; 50,000/ul absolute granulocyte count &gt; = 750 ul HIGHDOSE CHEMOTHERAPY : Adequate pulmonary function adult ( old 16 year ) : FEV1 &gt; 2 liter , room air PaO2 &gt; 70 mm Hg , room air PaCO2 &lt; 42 mm Hg , DLCO &gt; 50 % predict ; child ( young 16 year ) : DLCO &gt; 50 % predict HIGHDOSE CHEMOTHERAPY : Pretreatment test clinical laboratory test must perform within 4 week prior initiation highdose chemotherapy HIGHDOSE CHEMOTHERAPY : No medical and/or psychosocial problem opinion primary physician principal investigator would place patient unacceptable risk regimen HIGHDOSE CHEMOTHERAPY : Greater 2week period recovery prior modality use control primary recurrent site Exclusion Histologically confirm bone marrow metastasis within 30 day prior transplant ; prior bone marrow metastases clear bone marrow ( &lt; 5 % contamination measure bilateral bone marrow biopsy ) time evaluation protocol acceptable Karnofsky performance status &lt; 60 % Lansky performance status &lt; 50 % patient young 16 year old Females reproductive age use adequate birth control measure pregnant HIV disease Patients prior treatment myeloablative therapy exclude</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>